Clinical trial
Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung…
NCT00022711 · Fox Chase Cancer Center, Other · Completed
Key facts
| NCT number | NCT00022711 |
|---|---|
| Title | Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer |
| Official title | A Phase II Study of Temozolomide (SCH 52365) in the Treatment of Patients With Relapsed Small Cell Lung Cancer |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | temozolomide |
| Enrollment | 7 |
| Start date | Jan 1, 2002 |
| Primary completion | Jan 1, 2004 |
| Completion | Jan 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 11, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: